COMMUNIQUÉS West-GlobeNewswire

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration
28/07/2025
Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at Week 32 of [...]
ProMIS Neurosciences Announces Private Placement Financing
28/07/2025
$3 million private financing plus an additional $9 million of proceeds due to exercise of warrants, for gross proceeds of approximately $12.0 million TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 28, 2025 (GLOBE [...]
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025
28/07/2025
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second [...]
Kraig Biocraft Laboratories Signs Landmark Collaborative Agreement with Government Agency in Southeast Asia to Advance Spider Silk Production
28/07/2025
ANN ARBOR, Mich., July 28, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced the formal signing of a multi- [...]
Bio Usawa Biotechnology (Bio Usawa) Partners with DEK Vaccines Ltd (DEK) to Expand Access to Life-Saving Biopharmaceuticals Across Ghana and West Africa
28/07/2025
Strategic Distribution Agreement Aims to Address Africa's Growing Non-Communicable Disease Burden with Affordable, World-Class Therapies KIGALI, Rwanda and SAN FRANCISCO and ACCRA, Ghana , July 28, 2025 (GLOBE NEWSWIRE [...]
Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy
28/07/2025
– ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms – – Neuroimaging Biomarkers Showed Target Engagement and Slowed Brain Atrophy – – ATH434 was Well- [...]
Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative
28/07/2025
Liminatus Identifies BNB Coin as Its Primary Strategic Target for Digital Asset Allocation, with Plans to Aggressively Accumulate and Hold Up to $500 Million for Long-Term Strategic Value LA PALMA, Calif., July 28, 2025 [...]
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis
28/07/2025
JERUSALEM, July 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response to a Type A meeting [...]
HealthLynked Launches New Enterprise Healthcare Solutions Website and Upgraded Provider Directory to Expand Strategic Value Across the Healthcare Market
28/07/2025
NAPLES, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK ), a pioneer in healthcare technology and patient engagement, today announced the launch of its newly designed Enterprise [...]
Sotera Health Announces Second-Quarter 2025 Earnings Release Date
28/07/2025
CLEVELAND, July 28, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare [...]
La Commission européenne approuve l’IMBRUVICA® (ibrutinib) comme premier traitement ciblé pour les patients atteints d’un lymphome à cellules du manteau non préalablement traité et éligibles à une autogreffe de cellules souches
28/07/2025
L’ibrutinib est le premier inhibiteur de la tyrosine kinase de Bruton (BTK) approuvé qui a démontré des résultats statistiquement significatifs par rapport à l’autogreffe de cellules souches (AGCS) dans le traitement de [...]
Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter
28/07/2025
ST. LOUIS, July 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food [...]
Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)
28/07/2025
Lu177-B7H3 monoclonal antibody is first in class targeted radiopharmaceutical in development against the 4lg subtype of B7-H3 On track to initiate first-in-human study of RV-01 in solid tumors in 4Q25 SYDNEY, July 28, [...]
LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia
28/07/2025
Submission of NDA for LNZ100 in China by CORXEL Pharmaceuticals results in achievement of first milestone due to LENZ under the Development and Commercialization Agreement SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- [...]
Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
28/07/2025
SYDNEY, AUSTRALIA, July 28, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces [...]
OncoC4 Announces New Preclinical Data Highlighting ONC-841, a Novel SIGLEC 10 Antibody, as a Potential New Class of Therapeutics for Alzheimer’s Disease
28/07/2025
SIGLEC 10 identified as a genetic driver for amyloid plaque formation in mice ONC-841 blockade reduced amyloid plaques, normalized microglia function, and improved memory in preclinical Alzheimer’s disease mouse models [...]
Apyx Medical Corporation Announces Launch of Renuvion® in China
28/07/2025
Strong clinical interest and early procedures completed Entered into distribution agreement with GlamMoon, a division of BeauCare Clinics Investment Co., Ltd. post-initial market clearance CLEARWATER, Fla., July 28, [...]
Chiesi Global Rare Diseases Spotlights the Profound Impact of Epidermolysis Bullosa in the Film “Living Between Pain and Hope” as part of “The Next Frontier,” a New Series Presented by the Biotechnology Innovation Organization
28/07/2025
BOSTON, July 28, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases (Chiesi) proudly shares its contribution to the thought-provoking film "Living Between Pain and Hope," as part of “The Next Frontier,” a series [...]
Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET
28/07/2025
REDWOOD CITY, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced [...]

Pages